Alterations in Metabotropic Glutamate Receptor 1α and Regulator of G Protein Signaling 4 in the Prefrontal Cortex in Schizophrenia

Department of Psychiatry, University of Pittsburgh, PA 15213, USA.
American Journal of Psychiatry (Impact Factor: 12.3). 10/2010; 167(12):1489-98. DOI: 10.1176/appi.ajp.2010.10030318
Source: PubMed


Certain cognitive deficits in individuals with schizophrenia have been linked to disturbed gamma-aminobutyric acid (GABA) and glutamate neurotrans-mission in the prefrontal cortex. Thus, it is important to understand how the mechanisms that regulate GABA and glutamate neurotransmission are altered in schizophrenia. For example, group I metabo-tropic glutamate receptors (mGluR1α, mGluR5) modulate both GABA and gluta-mate systems. In addition, regulator of G protein signaling 4 (RGS4) reduces intra-cellular signaling through several different G protein-coupled receptors, including group I mGluRs. Finally, the endocannabinoid system plays an important role in regulating GABA and glutamate neurotrans-mission. The status of endocannabinoid ligands, such as 2-arachidonoylglycerol, can be inferred in part through measures of diacylglycerol lipase and monoglyceride lipase, which synthesize and degrade 2-arachidonoylglycerol, respectively.
Quantitative polymerase chain reaction was used to measure mRNA levels for group I mGluRs, RGS4, and markers of the endocannabinoid system in the prefrontal cortex Brodmann's area 9 of 42 schizophrenia subjects and matched normal comparison subjects. Similar analyses in monkeys chronically exposed to haloperidol, olanzapine, or placebo were also conducted.
Schizophrenia subjects had higher mRNA levels for mGluR1α and lower mRNA levels for RGS4, and these differences did not appear to be attributable to antipsychotic medications or other potential confounds. In contrast, no differences between subject groups were found in mRNA levels for endocannabinoid synthesizing and metabolizing enzymes.
Together, higher mGluR1α and lower RGS4 mRNA levels may represent a disturbed "molecular hub" in schizophrenia that may disrupt the function of prefrontal cortical networks, including both GABA and glutamate systems.

Download full-text


Available from: Stephen Eggan, Mar 29, 2014
  • Source
    • "Interestingly, ABHD6 is co-localized with the 2-AG synthesizing enzyme diacylglycerol lipase in the dendritic spines of pyramidal neurons in the PFC (Yoshida et al., 2006; Marrs et al., 2010; Ludanyi et al., 2011). In the same cohort of subjects, we previously reported that mRNA levels for diacylglycerol lipase are not altered in the PFC in schizophrenia (Volk et al., 2010). Importantly , higher ABHD6 mRNA levels without changes in diacylglycerol lipase lead to higher metabolism of 2-AG (Marrs et al., 2010, 2011; Navia-Paldanius et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adolescent cannabis use is associated with greater relative risk, increased symptom severity, and earlier age of onset of schizophrenia. We investigated whether this interaction may be partly attributable to disease-related disturbances in metabolism of the major cortical endocannabinoid 2-arachidonoylglycerol (2-AG). Transcript levels for the recently discovered 2-AG metabolizing enzyme, α-β-hydrolase domain 6 (ABHD6), were assessed using quantitative PCR in the prefrontal cortex of schizophrenia and healthy subjects (n=84) and antipsychotic- or tetrahydrocannabinol-exposed monkeys. ABHD6 mRNA levels were elevated in schizophrenia subjects who were younger and had a shorter illness duration but not in antipsychotic- or tetrahydrocannabinol-exposed monkeys. Higher ABHD6 mRNA levels may increase 2-AG metabolism which may influence susceptibility to cannabis in the earlier stages of schizophrenia.
    Schizophrenia Research 04/2013; 147(1). DOI:10.1016/j.schres.2013.02.038 · 3.92 Impact Factor
  • Source
    • "Conversely, schizophrenia is associated with the increased expression of receptors that promote Ca +2 -cAMP signaling. For example, there is increased expression of mGluR1a (Volk et al., 2010), which evokes internal Ca release (Figure 8E; image from Muly et al., 2003), and increased expression of D1R even in drug naive patients (Abi-Dargham et al., 2012), which would increase the generation of cAMP signaling (Figure 8F). Although it is possible that the increase in D1R compensates for reduced DA levels in dlPFC, it is not known if DA is altered in PFC at this early stage of disease (see below). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This review describes unique neuromodulatory influences on working memory prefrontal cortical (PFC) circuits that coordinate cognitive strength with arousal state. Working memory arises from recurrent excitation within layer III PFC pyramidal cell NMDA circuits, which are afflicted in aging and schizophrenia. Neuromodulators rapidly and flexibly alter the efficacy of these synaptic connections, while leaving the synaptic architecture unchanged, a process called dynamic network connectivity (DNC). Increases in calcium-cAMP signaling open ion channels in long, thin spines, gating network connections. Inhibition of calcium-cAMP signaling by stimulating α2A-adrenoceptors on spines strengthens synaptic efficacy and increases network firing, whereas optimal stimulation of dopamine D1 receptors sculpts network inputs to refine mental representation. Generalized increases in calcium-cAMP signaling during fatigue or stress disengage dlPFC recurrent circuits, reduce firing and impair top-down cognition. Impaired DNC regulation contributes to age-related cognitive decline, while genetic insults to DNC proteins are commonly linked to schizophrenia.
    Neuron 10/2012; 76(1):223-39. DOI:10.1016/j.neuron.2012.08.038 · 15.05 Impact Factor
  • Source
    • "In a genome wide linkage study, an association was found between a factor-analytically derived schizophrenia subtype with severe disorganization and negative symptoms and a susceptibility locus on chromosome 1q23-25 (Holliday et al., 2009). The best-studied gene in that region is the regulator of G protein signaling 4 (RGS4) gene, which is involved in glutamate systems and is thought to have downstream effects on the NMDA receptor (Volk et al., 2010). RGS4 expression is downregulated in the prefrontal cortex and superior temporal gyrus in schizophrenia (Prasad et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is considerable variation in progressive brain volume changes in schizophrenia. Whether this is related to the clinical heterogeneity that characterizes the illness remains to be determined. This study examines the relationship between change in brain volume over time and individual variation in psychopathology, as measured by five continuous symptom dimensions (i.e. negative, positive, disorganization, mania and depression). Global brain volume measurements from 105 schizophrenia patients and 100 healthy comparison subjects, obtained at inclusion and 5-year follow-up, were used in this study. Symptom dimension scores were calculated by factor analysis of clinical symptoms. Using linear regression analyses and independent-samples t-tests, the relationship between symptom dimensions and progressive brain volume changes, corrected for age, gender and intracranial volume, was examined. Antipsychotic medication, outcome and IQ were investigated as potential confounders. In patients, the disorganization dimension was associated with change in total brain (β=-0.295, p=0.003) and cerebellar (β=-0.349, p<0.001) volume. Furthermore, higher levels of disorganization were associated with lower IQ, irrespective of psychiatric status (i.e. patient or control). In healthy comparison subjects, disorganization score was not associated with progressive brain volume changes. Heterogeneity in progressive brain volume changes in schizophrenia is particularly associated with variation in disorganization. Schizophrenia patients with high levels of disorganization exhibit more progressive decrease of global brain volumes and have lower total IQ. We propose that these patients form a phenotypically and biologically homogenous subgroup that may be useful for etiological (e.g., genetic) studies.
    Schizophrenia Research 04/2012; 138(2-3):171-6. DOI:10.1016/j.schres.2012.03.036 · 3.92 Impact Factor
Show more